Clinical trial NCT05922462: Effects of Increased Greek Yogurt Consumption in Youth and Young Adult Athletes
Official title: Effects of Increased Greek Yogurt Consumption on Circulating Markers of Bone Metabolism and Inflammation in Youth and Young Adult Athletes
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Bone Growth Abnormal
Inflammation
Keywords: Athletes
Bone markers
Inflammatory cytokines
Greek yogurt
Whey protein
Lead sponsor: Brock University
Sponsor class: OTHER
Collaborators: name: York University
First posted: 2023-06-28
Enrollment: 40
Sex: ALL
Minimum age (years): 15
Maximum age (years): 22
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: The study will use a randomized controlled parallel design, where participants will be randomly assigned to either to consume greek yogurt or whey protein for 16 weeks.
Primary purpose: PREVENTION

Brief summary: Physical activity and dairy consumption during growth and development are each known to improve peak bone mass in young adults. Peak bone mass, the maximum amount of bone a person will have in their lifetime, is typically reached in the early 20's in females and late 20's in males. However, evidence suggests that young people do not consume enough dairy to maximize their bone mass. The resulting effect in peak bone mass can be troublesome, particularly for athletes, such as volleyball players. This study aims to determine whether increased dairy consumption combined with training can have an additive effect on the physiology of young competitive athletes. Specifically, we will examine whether Greek yogurt consumption will lead to beneficial changes in bone metabolism and inflammation, in adolescent and young adult, male and female athletes, similar to those observed with whey protein supplementation. Many athletes choose exclusively protein supplementation and miss out on other nutrients vital for healthy growth and development. By examining the benefits of Greek yogurt across different athlete age groups and sexes, this work will help reshape the attitudes, beliefs, and behaviours surrounding diet of young athletes.

Detailed description: Purpose: This study will investigate the effect of chronic high-impact exercise training and GY consumption on bone metabolism and inflammation compared with isonitrogenous/isocaloric whey protein (WP) supplementation (a common practice by athletes) in youth and young adult athletes.

Participants: A total of 40 varsity athletes (aged 17-22 years; 20 males, 20 females) will be recruited in year one, and 40 club athletes (aged 15-16 years; 20 males, 20 females) will be recruited in year two. Participants will be recruited from the varsity teams at Brock and club teams in the Niagara area (one male and one female team from each age group). All participants (and the parents/guardians of club athletes) will provide written informed consent in order to be included in the study. Potential participants will complete an online health screening questionnaire to document general health and individual and family health history. It will also be used to record information on medication use and for female participants to report menstrual history and status, as well as the use and type of oral contraceptives (brand and hormone). Athletes will be excluded from the study if they are injured and unable to participate in practices, have an allergy to dairy foods/dairy protein or have been diagnosed with lactose intolerance.

Athletes from each team will be randomly assigned to either the GY intervention group or the WP comparison group. Thus, eight treatment groups (n = 10 athletes per group):

* GY x Female Varsity
* GY x Male Varsity
* GY x Female Club
* GY x Male Club
* WP x Female Varsity
* WP x Male Varsity
* WP x Female Club
* WP x Male Club

Study Design and Procedures: The study will follow a randomized controlled parallel design over a two-year period. At the beginning of their training season, varsity (year one) and club athletes (year two) will be invited to participate in this 24-week study, consisting of an 8-week control condition (September to November) and a 16-week intervention condition (November to March).

Control Condition: During the 8-week control condition, participants will be instructed to follow their typical, habitual diet and training protocols. Seven-day food records will be completed by participants and assessed by a registered dietitian (RD) using the Keenoa online food tracker application in order to determine baseline dairy, calcium, and protein, intake levels in their habitual diets during the competitive season.

Intervention Condition: During the 16-week intervention condition, participants will be randomly assigned to either the GY or WP group. To monitor adherence, all participants will be asked to log their daily GY or WP intake.

Participants in the GY group will be instructed by the RD to consume 2 servings/day of 175 g commercially available GY (0% MF, flavoured, 130 calories, 17 g protein, 225 g calcium; e.g., OIKOS High Protein GY) for a total of 16 weeks. This serving amount has been used in the investigators' previous study in adolescent female soccer players, but slightly lower than in recreationally active adult males. For their convenience, the athletes will be provided with appropriate scoops to measure out 175 g of GY per serving of the larger 650 g commercially available, pre-packaged containers. Although it is recommended to consume the two servings morning and night, to increase ecological validity and strengthen the feasibility of the intervention, the timing of the servings will be flexible to facilitate the training and competition routines. For the same reasons, the athletes will be able to choose the flavour of their GY.

Participants in the WP group will follow a similar consumption schedule but will be instructed by the RD to consume two servings/day of 2/3 of a scoop of commercially available WP powder (flavoured, \~29 g, 120 calories, 19 g protein, 112.5 g calcium; e.g., PURE Whey Protein, Walmart) for a total of 16 weeks. The WP scoop will be dissolved in water (e.g., 1 g of WP isolate to 10 mL of water, as recommended by the manufacturer). This protein dose is similar to the previous dose in young swimmers and comparable to other studies in adults. Athletes will be provided with appropriately marked scoops (corresponding to 2/3 of the manufacturer scoop) to measure their single servings.

For the duration of both the GY and WP intervention condition (16 weeks), participants will be asked to maintain their habitual intakes (as per what they were doing in the control condition). That is, they will not be asked to stop any other protein supplementation they may have been taking during the control condition. The GY/WP servings during the intervention condition will be added to their habitual diet. Participants will be asked to track their daily dietary intake several times during the study (weeks 0, 8, 16, and 24), including all food, liquids, and supplements, using the Keenoa online food tracker application. Despite the added energy intake from the GY/WP, we do not expect any (significant) weight gain with the added \~300 calories per day due to the athletes' high energy expenditures.

Blood Samples: All participants will be instructed not to consume any food or liquids (except water, as needed) 8 hours prior to the time of their blood draw, not to exercise for 12 hours prior to the blood draw, and not to make any changes to their normal routines. A total of 10 mL of blood will be collected from an antecubital vein by a certified phlebotomist or registered nurse using a standard venipuncture technique at four timepoints: weeks 0, 8,16, and 24. All blood samples will be centrifuged at 1,405 x g at 4°C for 10 min. Serum and plasma will be aliquoted into pre-labeled Eppendorf tubes and stored at -80°C until analysis. The serum concentrations of markers and regulators of bone remodelling (osteocalcin, P1NP, CTX, OPG, sclerostin, RANKL, PTH), and the plasma concentrations of inflammatory cytokines (IL6, IL10, TNFα), sex hormones (estrogen, testosterone) and growth factors (IGF-1) will be measured in duplicate using commercially available ELISA kits.

Bone Properties: Transaxial quantitative ultrasound (QUS; Sunlight Omnisense™ 7000S, Sunlight Medical, Israel) will be used at weeks 0, 8, 16, and 24 to assess bone strength by measuring the speed of sound (SOS; m/s) along the bone at the distal 1/3 of the radius and at the mid-tibia of the dominant limbs, as previously described. The strength of bone is determined by the shortest time elapsed between the transmission and reception of the signal transmitted, with faster transmissions reflecting stronger bone. QUS can be used for the assessment of bone strength and is particularly suited for studies in healthy populations as it is portable, relatively inexpensive, and non-invasive (no radiation exposure). Because QUS measures the SOS along the bone it is not affected by bone size, thus allowing for comparisons between participants of different sizes. QUS has been previously used by the principal investigator and others to demonstrate the effect of exercise training or physical activity on various bones and in different age groups, including children.

Body Composition: Body mass (kg) and body composition will be measured using bioelectrical impedance analysis (BIA; InBody520 bioelectrical impedance analysis system following standard procedures.

Dietary Assessment: Participants' dietary intake, including energy intake, as well as macronutrient, micronutrient, vitamin, and supplement intakes will be recorded at weeks 0, 8, 16, and 24 using the Keenoa food application. Using the same application, participants will be asked to log their daily GY or WP intake in order to monitor adherence. In addition, participants' knowledge of nutrition will be assessed at the beginning (week 0) and completion of the study (week 24) using the self-reported 97-item GeSNK. The GeSNK encompasses 64 items assessing general and sport-specific nutrition knowledge, with the aim of exploring knowledge regarding macro- and micronutrients in various food choices, and awareness of diet-health associations, knowledge of fluid replacement, supplement intake, and food choices in regard to sport recovery meals. The GeSNK will be completed online along with the medical screening questions used to screen for inclusion criteria.

Training Volume and Physical Activity: Training logs will be collected from participants and coaches every week throughout the study. In addition, leisure-time physical activity will be assessed using the GSLTPAQ modified for the purpose of this study. The GSLTPAQ evaluates leisure-time physical activity using indicators of the intensity of exertion as light, moderate, vigorous, or very vigorous. Weekly physical activity metabolic equivalents are estimated based on the number of 15 min blocks at each intensity level multiplied by assumed energy consumption values. The GSLTPAQ is a standardized tool that has been demonstrated to be valid and reliable in children, adolescents, and adults.

Statistical Analysis: The data analysis with all ages combined using age and/or training volume as covariates will be performed leading to at least one additional publication and presentation. Prior to analysis, all variables will be tested for normality by visual inspection of histograms and z-scores (± 3) and by assessing the skewness and kurtosis (± 3). For dependent variables that are normally distributed, a series of two-way repeated measures analysis of variances with sex or age/training volume as covariates (RM-ANCOVAs) will be used to examine changes over time with main effects and interactions for the intervention conditions (GY vs WP) and time (0, 8, 16, and 24 weeks) on body composition and biochemical markers. In the event of a significant interaction or a main effect for time, posthoc pairwise comparisons will be performed with Bonferroni adjustment for multiple comparisons. If the assumption of sphericity is violated, the Greenhouse Geisser correction factor will be used. Dependent variables that may not be normally distributed will be log-transformed before the analysis. The significance level will be set at p \<0.05.

Sample Size: Using G\*Power analysis for an RM-ANCOVA (2 intervention groups, 4 timepoints, sex as covariate), we calculated that a total sample size of n = 36 (i.e., 18 per intervention group) would be required to detect a medium effect of partial η2 = 0.06 with a power of (1-β) = 0.90, and a probability level of p = 0.05. Thus, the proposed total of 40 participants (40 varsity and 40 club athletes) is more than adequate to detect significant effects and interactions, while allowing for a 20% attrition rate.

Eligibility criteria: Inclusion Criteria:

* Competitive youth or varsity athletes

Exclusion Criteria:

* Presence of injury
* Inability to participate in practices
* Allergy to dairy foods/dairy protein or
* Diagnosis with lactose intolerance

Primary outcomes:
measure: Osteocalcin
timeFrame: Baseline (week 0)
measure: Osteocalcin
timeFrame: End of control period and pre-intervention (week 8)
measure: Osteocalcin
timeFrame: Middle of intervention period (week 16)
measure: Osteocalcin
timeFrame: Completion of intervention period (week 24)
measure: Amino-terminal propeptide of type I collagen (P1NP)
timeFrame: Baseline (week 0)
measure: Amino-terminal propeptide of type I collagen (P1NP)
timeFrame: End of control period and pre-intervention (week 8)
measure: Amino-terminal propeptide of type I collagen (P1NP)
timeFrame: Middle of intervention period (week 16)
measure: Amino-terminal propeptide of type I collagen (P1NP)
timeFrame: Completion of intervention period (week 24)
measure: Osteoprotegerin (OPG)
timeFrame: Baseline (week 0)
measure: Osteoprotegerin (OPG)
timeFrame: End of control period and pre-intervention (week 8)
measure: Osteoprotegerin (OPG)
timeFrame: Middle of intervention period (week 16)
measure: Osteoprotegerin (OPG)
timeFrame: Completion of intervention period (week 24)
measure: C-telopeptides of type I collagen (CTX)
timeFrame: Baseline (week 0)
measure: C-telopeptides of type I collagen (CTX)
timeFrame: End of control period and pre-intervention (week 8)
measure: C-telopeptides of type I collagen (CTX)
timeFrame: Middle of intervention period (week 16)
measure: C-telopeptides of type I collagen (CTX)
timeFrame: Completion of intervention period (week 24)
measure: Sclerostin
timeFrame: Baseline (week 0)
measure: Sclerostin
timeFrame: End of control period and pre-intervention (week 8)
measure: Sclerostin
timeFrame: Middle of intervention period (week 16)
measure: Sclerostin
timeFrame: Completion of intervention period (week 24)
measure: Receptor activator of nuclear factor kappa-Β ligand (RANKL)
timeFrame: Baseline (week 0)
measure: Receptor activator of nuclear factor kappa-Β ligand (RANKL)
timeFrame: End of control period and pre-intervention (week 8)
measure: Receptor activator of nuclear factor kappa-Β ligand (RANKL)
timeFrame: Middle of intervention period (week 16)
measure: Receptor activator of nuclear factor kappa-Β ligand (RANKL)
timeFrame: Completion of intervention period (week 24)
measure: Parathyroid hormone (PTH)
timeFrame: Baseline (week 0)
measure: Parathyroid hormone (PTH)
timeFrame: End of control period and pre-intervention (week 8)
measure: Parathyroid hormone (PTH)
timeFrame: Middle of intervention period (week 16)
measure: Parathyroid hormone (PTH)
timeFrame: Completion of intervention period (week 24)
measure: Interleukin-6 (IL6)
timeFrame: Baseline (week 0)
measure: Interleukin-6 (IL6)
timeFrame: End of control period and pre-intervention (week 8)
measure: Interleukin-6 (IL6)
timeFrame: Middle of intervention period (week 16)
measure: Interleukin-6 (IL6)
timeFrame: Completion of intervention period (week 24)
measure: Interleukin-10 (IL10)
timeFrame: Baseline (week 0)
measure: Interleukin-10 (IL10)
timeFrame: End of control period and pre-intervention (week 8)
measure: Interleukin-10 (IL10)
timeFrame: Middle of intervention period (week 16)
measure: Interleukin-10 (IL10)
timeFrame: Completion of intervention period (week 24)
measure: Tumour necrosis factor-alpha (TNFα)
timeFrame: Baseline (week 0)
measure: Tumour necrosis factor-alpha (TNFα)
timeFrame: End of control period and pre-intervention (week 8)
measure: Tumour necrosis factor-alpha (TNFα)
timeFrame: Middle of intervention period (week 16)
measure: Tumour necrosis factor-alpha (TNFα)
timeFrame: Completion of intervention period (week 24)
Secondary outcomes:
measure: Insulin-like growth factor 1 (IGF1)
timeFrame: Baseline (week 0)
measure: Insulin-like growth factor 1 (IGF1)
timeFrame: End of control period and pre-intervention (week 8)
measure: Insulin-like growth factor 1 (IGF1)
timeFrame: Middle of intervention period (week 16)
measure: Insulin-like growth factor 1 (IGF1)
timeFrame: Completion of intervention period (week 24)
measure: Testosterone
timeFrame: Baseline (week 0)
measure: Testosterone
timeFrame: End of control period and pre-intervention (week 8)
measure: Testosterone
timeFrame: Middle of intervention period (week 16)
measure: Testosterone
timeFrame: Completion of intervention period (week 24)
measure: Estrogen
timeFrame: Baseline (week 0)
measure: Estrogen
timeFrame: End of control period and pre-intervention (week 8)
measure: Estrogen
timeFrame: Middle of intervention period (week 16)
measure: Estrogen
timeFrame: Completion of intervention period (week 24)
measure: Body mass
timeFrame: Baseline (week 0)
measure: Body mass
timeFrame: End of control period and pre-intervention (week 8)
measure: Body mass
timeFrame: Middle of intervention period (week 16)
measure: Body mass
timeFrame: Completion of intervention period (week 24)
measure: Fat mass
timeFrame: Baseline (week 0)
measure: Fat mass
timeFrame: End of control period and pre-intervention (week 8)
measure: Fat mass
timeFrame: Middle of intervention period (week 16)
measure: Fat mass
timeFrame: Completion of intervention period (week 24)
measure: Lean mass
timeFrame: Baseline (week 0)
measure: Lean mass
timeFrame: End of control period and pre-intervention (week 8)
measure: Lean mass
timeFrame: Middle of intervention period (week 16)
measure: Lean mass
timeFrame: Completion of intervention period (week 24)
measure: Body fat percentage
timeFrame: Baseline (week 0)
measure: Body fat percentage
timeFrame: End of control period and pre-intervention (week 8)
measure: Body fat percentage
timeFrame: Middle of intervention period (week 16)
measure: Body fat percentage
timeFrame: Completion of intervention period (week 24)
measure: Height
timeFrame: Baseline (week 0)
measure: Height
timeFrame: End of control period and pre-intervention (week 8)
measure: Height
timeFrame: Middle of intervention period (week 16)
measure: Height
timeFrame: Completion of intervention period (week 24)
measure: Bone Properties
timeFrame: Baseline (week 0)
measure: Bone Properties
timeFrame: End of control period and pre-intervention (week 8)
measure: Bone Properties
timeFrame: Middle of intervention period (week 16)
measure: Bone Properties
timeFrame: Completion of intervention period (week 24)
measure: Dietary intake (kcal/day)
timeFrame: Baseline (week 0)
measure: Dietary intake (kcal/day)
timeFrame: End of control period and pre-intervention (week 8)
measure: Dietary intake (kcal/day)
timeFrame: Middle of intervention period (week 16)
measure: Dietary intake (kcal/day)
timeFrame: Completion of intervention period (week 24)
measure: Energy expenditure (kcal/week)
timeFrame: Baseline (week 0)
measure: Energy expenditure (kcal/week)
timeFrame: End of control period and pre-intervention (week 8)
measure: Energy expenditure (kcal/week)
timeFrame: Middle of intervention period (week 16)
measure: Energy expenditure (kcal/week)
timeFrame: Completion of intervention period (week 24)
measure: Training volume (hours/week)
timeFrame: Baseline (week 0)
measure: Training volume (hours/week)
timeFrame: End of control period and pre-intervention (week 8)
measure: Training volume (hours/week)
timeFrame: Middle of intervention period (week 16)
measure: Training volume (hours/week)
timeFrame: Completion of intervention period (week 24)
measure: Nutrition knowledge
timeFrame: Baseline (week 0)
measure: Nutrition knowledge
timeFrame: Completion of intervention period (week 24)
Other outcomes:
Locations:
city: St. Catharines
country: Canada
facility: Brock University
state: Ontario
Study officials:
affiliation: Brock University
name: Panagiota Klentrou, PhD
role: PRINCIPAL_INVESTIGATOR
References: